Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD8233 Following Multiple Ascending Subcutaneous Dose Administration in Subjects With Dyslipidemia With or Without Type 2 Diabetes

NCT04155645 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT04155645
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04155645 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD8233 Following Multiple Ascending Subcutaneous Dose Administration in Subjects With Dyslipidemia With or Without Type 2 Diabetes
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Completed
Start date
November 21, 2019
Completion date
June 7, 2021
Enrollment
34 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

dyslipidemia